These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1757611)

  • 1. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.
    Herz G; Blum G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1166-9. PubMed ID: 1757611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.
    Blum G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1153-6. PubMed ID: 1757607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis.
    Goldberg B; Hartdegen R; Presbury D; Smith EH; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1145-8. PubMed ID: 1757605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus.
    Brunner N; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1160-3. PubMed ID: 1757609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus.
    Datz B; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1157-60. PubMed ID: 1757608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis.
    Mensing H; Korsukewitz G; Yawalkar S
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1149-52. PubMed ID: 1757606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.
    Yawalkar SJ; Schwerzmann L
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1163-6. PubMed ID: 1757610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses.
    Guzzo CA; Weiss JS; Mogavero HS; Ellis CN; Zaias N; Lowe NJ; Kerdel FA; Milbauer JJ; Bernhard JD; Whitmore C
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1179-83. PubMed ID: 1757614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies.
    Bernhard J; Whitmore C; Guzzo C; Kantor I; Kalb RE; Ellis C; Urbach F; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1170-4. PubMed ID: 1757612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses.
    Kantor I; Cook PR; Cullen SI; Willis I; Gibson JR; Stanfield JW
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1184-6. PubMed ID: 1757615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis.
    Katz HI; Gross E; Buxman M; Prawer SE; Schwartzel EH; Gibson JR
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1175-8. PubMed ID: 1757613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and topical therapy.
    Lebwohl M
    Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.
    Lebwohl M; Siskin SB; Epinette W; Breneman D; Funicella T; Kalb R; Moore J
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):268-9. PubMed ID: 8708035
    [No Abstract]   [Full Text] [Related]  

  • 14. Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate.
    Yawalkar S; Wiesenberg-Boettcher I; Gibson JR; Siskin SB; Pignat W
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1137-44. PubMed ID: 1757603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 16. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
    Grove G; Zerweck C; Houser T; Andrasfay A; Gauthier B; Holland C; Piacquadio D
    J Drugs Dermatol; 2017 Feb; 16(2):140-144. PubMed ID: 28300856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
    Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halobetasol propionate for the management of psoriasis.
    Bagel J; Thibodeaux QG; Han G
    Cutis; 2020 Feb; 105(2):92-96;E4. PubMed ID: 32186526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.
    Desai SR; Glick B; Del Rosso JQ; Harris S; Jacobson A
    J Drugs Dermatol; 2021 Mar; 20(3):252-258. PubMed ID: 33683083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.